The Food and Drug Administration (FDA) has approved Endo’s Abbreviated New Drug Application (ANDA) for the first generic version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules.
Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride capsules are indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori.
Each capsule contains 140mg of bismuth subcitrate potassium, 125mg of metronidazole, a nitroimidazole antimicrobial, and 125mg of tetracycline hydrochloride, a tetracycline class antimicrobial. The product is supplied as a 10 day therapy pack containing 10 blister cards, with each card containing 12 capsules for a total of 120 capsules.
Par Pharmaceuticals announced that shipping of the generic product has commenced.
- Endo launches first generic version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules. News release. Endo International plc. Accessed March 10, 2023. https://www.prnewswire.com/news-releases/endo-launches-first-generic-version-of-pylera-bismuth-subcitrate-potassium-metronidazole-tetracycline-hydrochloride-capsules-301768573.html.
- Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride capsules. Package insert. Endo International plc; 2023. Accessed March 10, 2023. https://www.endodocuments.com/documents/Bismuth/Bismuth_PI.pdf.
This article originally appeared on MPR
Log in to continue reading this article.
Don’t miss out on today’s top content on The Medical Bag. Register for free and gain unlimited access to the latest in medical news, and lifestyle and business advice, with personalized daily picks for you. There’s something for every health care professional on The Medical Bag.
Want to read more?
Please login or register first to view this content.